Last reviewed · How we verify

NCT03883984

Cysteamine for Asthma

Completed Phase 1 Last updated 6 May 2021
What this trial tests

Phase 1 trial testing Cysteamine Bitartrate in Asthma in 60 participants. Completed in 10 February 2021.

Timeline
18 June 2019
Primary endpoint
10 February 2021
10 February 2021

Quick facts

Lead sponsorChildren's Hospital Medical Center, Cincinnati
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment60
Start date18 June 2019
Primary completion10 February 2021
Estimated completion10 February 2021
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Children's Hospital Medical Center, Cincinnati

Who can join

Adults 18 to 45, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to see if a medicine called Cysteamine, given along with standard asthma care, will improve asthma symptoms and lung function.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Macrophages: Subtypes, Distribution, Polarization, Immunomodulatory Functions, and Therapeutics.
    Peng M, Li N, Wang H, Li Y, et al · · 2025 · cited 12× · PMID 40717900 · DOI 10.1002/mco2.70304

Verify or expand the search:

Other trials of Cysteamine Bitartrate

Trials testing the same drug.

Other recruiting trials for Asthma

Currently open trials in the same condition.

Other Children's Hospital Medical Center, Cincinnati trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03883984.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing